Bosutinib in the management of chronic myelogenous leukemia
Biologics: Targets & Therapy, 2013 Gunhild Keller-von Amsberg, Philippe SchafhausenDepartment of Hematology and Oncology and, Stem Cell Transplantation and Pulmonology Division, Oncological Center, University Hospital Hamburg-Eppendorf, Hamburg, GermanyAbstract: Bosutinib (SKI-606) is an ...
Keller-von Amsberg G, Schafhausen P
doaj
DNA self-assembly nanoflower reverse P-glycoprotein mediated drug resistance in chronic myelogenous leukemia therapy. [PDF]
Front Bioeng Biotechnol, 2023 Zhao P +8 more
europepmc +1 more source
Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells. [PDF]
BMC Cancer, 2023 Okabe S, Gotoh A.
europepmc +1 more source
Chromosome banding studies in 106 cases of chronic myelogenous leukemia [PDF]
, 1982 Takafumi Tomiyasu +3 more
openalex +1 more source
Chronic myelogenous leukemia presenting with Morel Lavallée lesion: A case report of a rare presentation. [PDF]
Clin Case Rep, 2022 Mohamed SSI +7 more
europepmc +1 more source
Methyl-Thiol-Bridged Oxadiazole and Triazole Heterocycles as Inhibitors of NF-κB in Chronic Myelogenous Leukemia Cells. [PDF]
Biomedicines, 2023 Basappa B +9 more
europepmc +1 more source
Biochemical and Immunological Properties of Human Terminal Deoxynucleotidyl Transferase Purified from Blasts of Acute Lymphoblastic and Chronic Myelogenous Leukemia [PDF]
, 1981 Martin R. Deibel +3 more
openalex +1 more source
AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects. [PDF]
Cell Death Discov, 2023 Gayatri MB +6 more
europepmc +1 more source
Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia [PDF]
, 1980 DK Hasegawa +6 more
openalex +1 more source
CML-T1: a cell line derived from T-lymphocyte acute phase of chronic myelogenous leukemia [PDF]
, 1989 Kazutaka Kuriyama +9 more
openalex +1 more source